Since the Drug Supply Chain Security Act (DSCSA) was enacted nearly 10 years ago, healthcare supply chain stakeholders have made steady progress in meeting regularly (through HDA and other settings) to discuss compliance strategies, establish recommended guidelines and build consensus on key milestones.
Earlier this month, HDA published two new resources for supply chain stakeholders to ensure the proper handling of new products moving through the supply chain and removal of products that are recalled or need to be withdrawn.
HDA will be carrying forward the early lessons learned from COVID-19 pandemic and supporting response efforts in 2021, writes President and CEO Chip Davis in the January 4 issue of Chain Drug Review — particularly as distributors play a role in the largest public vaccination effort in recent memory. Davis provided his perspective on the year ahead, along with other healthcare trade association leaders, as part of the publication’s 2021 “Pharmacy Outlook” feature.
Since the enactment of the Drug Supply Chain Security Act in 2013, members of the pharmaceutical supply chain have undertaken efforts to meet each of the major milestones contained within the statute’s 10-year timeline to further secure the safety of the products being distributed. The industry’s progress to 2023 interoperability was top of mind as supply chain and other stakeholders came together at HDA’s recent Traceability Online Seminar.
With 2020 underway, HDA’s John M. Gray provided perspective on the vital role of pharmaceutical distributors and the Alliance’s policy priorities as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.